Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03978611 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT03978611 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 11 participants.
The verdict
NCT03978611, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The primary purpose of this study is to characterize the safety, tolerability, and dose-limiting toxicities (DLTs) of relatlimab in combination with ipilimumab.
Interventions
- DRUG Ipilimumab
- DRUG Relatlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2021-12-09 |
| Est. Completion | 2023-07-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03978611
The ClinicalTrials.gov registry entry for NCT03978611 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ipilimumab is the first listed.
NCT03978611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03978611 about?
NCT03978611 is a clinical study titled "A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment". The primary purpose of this study is to characterize the safety, tolerability, and dose-limiting toxicities (DLTs) of relatlimab in combination with ipilimumab.
What is the current status of trial NCT03978611?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2021-12-09. Estimated completion is 2023-07-26.
What interventions are being tested in trial NCT03978611?
The interventions under investigation include: Ipilimumab (DRUG), Relatlimab (DRUG).
Who is sponsoring clinical trial NCT03978611?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.